NCT03698448View on ClinicalTrials.gov

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 1, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

November 1, 2022

Conditions
Cystic Fibrosis
Interventions
DRUG

OligoG Dry powder for inhalation

10 capsules Dry Powder for Inhalation, BID

Trial Locations (1)

50924

CF Zentrum Köln, Universitätskrankenhaus Köln, Cologne

Sponsors

Lead Sponsor

AlgiPharma AS
All Listed Sponsors
collaborator

Imperial College London

OTHER

collaborator

Cystic Fibrosis Foundation

OTHER

collaborator

European Cystic Fibrosis Society

UNKNOWN

collaborator

University Hospital of Cologne

OTHER

collaborator

Cystic Fibrosis Europe

UNKNOWN

lead

AlgiPharma AS

INDUSTRY

NCT03698448 - A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis | Biotech Hunter | Biotech Hunter